Famitinib malate plus camrelizumab in patients with recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: A multicenter, open-label, single-arm, phase II trial

Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study

A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer

Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): Updated survival analysis

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

Dkn-01 treated patients with recurrent epithelial endometrial (EEC) or ovarian (EOC) cancers which harbor Wnt activating mutations have longer progression-free survival and improved clinical benefit

Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer

A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer: Presentation of safety data

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer (EOC): The SIERRA multi-institutional open-label phase Ib trial

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status

Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab